Once-daily treatment of rheumatoid arthritis with choline magnesium trisalicylate.

Abstract

A pilot study evaluated once-daily treatment of rheumatoid arthritis with choline magnesium trisalicylate (CMT) in patients diagnosed as having classical or definite rheumatoid arthritis, with morning stiffness as a major complaint. Twenty patients were selected who, in an earlier phase of the study, had found twice-daily treatment with CMT effective and tolerable. Efficacy was evaluated in 15 of these patients and safety was evaluated in all 20. Comparisons were made with the twice-daily regimen and with previous nonsteroidal anti-inflammatory drug (NSAID) therapy. Changes in clinical indicators (numbers of painful and swollen joints and the duration of morning stiffness) showed that once-daily treatment with CMT was as effective as twice-daily treatment with CMT or as treatment with other prior NSAIDs in controlling signs and symptoms of rheumatoid arthritis. Side effects in both the twice-daily and the once-daily treatment regimens were similar in incidence and nature.

• Authors: C C Mann, J T Boyer
• Journal: Clinical therapeutics (Clin Ther) Vol. 6 Issue 2 Pg. 170-7 ( 1984) ISSN: 0149-2918 [Print] United States
• PMID: 6705011 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Salicylates
• choline magnesium trisalicylate
• Choline

Topics

• Adult
• Aged
• Anti-Inflammatory Agents (administration & dosage, adverse effects)
• Arthritis, Rheumatoid (drug therapy)
• Choline (administration & dosage, adverse effects, analogs & derivatives)
• Female
• Hearing Loss (chemically induced)
• Humans
• Male
• Middle Aged
• Pilot Projects
• Salicylates (administration & dosage, adverse effects)
• Tinnitus (chemically induced)